Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For a subject with type 1 diabetes mellitus:
Male or female Chinese subjects aged 18-64 years (both inclusive) at the time of signing informed consent.
Type 1 diabetes mellitus (as diagnosed clinically) greater than or equal to 12 months prior to the day of screening.
Treated with multiple daily insulin injections or premix insulin greater than or equal to 12 months prior to the day of screening or treated with continuous subcutaneous insulin infusion (CSII) greater than or equal to 3 months prior to the day of screening.
Glycosylated haemoglobin (HbA1c) less than or equal to 9.0 percent (75 mmol/mol) by central laboratory analysis.
For a subject with type 2 diabetes mellitus:
Male or female Chinese subjects aged 18-75 years (both inclusive) at the time of signing informed consent.
Type 2 diabetes mellitus (as diagnosed clinically) greater than or equal to 12 months prior to the day of screening.
Treated with multiple daily insulin injections or premix insulin greater than or equal to 6 months prior to the day of screening or treated with continuous subcutaneous insulin infusion (CSII) greater than or equal to 3 months prior to the day of screening.
Glycosylated haemoglobin less than or equal to 9.5 percent (80 mmol/mol) by central laboratory analysis.
You may not be if
For a subject with type 1 diabetes mellitus or type 2 diabetes mellitus:
Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
Surgery or trauma with significant blood loss (more than 400 mL) within the last 3 months prior to screening.
Not able or willing to refrain from smoking and use of nicotine substitute products during the in-patient period.
